Analysen im Rahmen der klinischen Studie BAY 57-9352: Imp. 100521 Open label, phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and biomarker status of BAY 57-9352 (KDR\VEGFR2-inhibitor) in a continuous dose schedule in subjects with advanced malignancies (in collaboration with Bayer B.V., division Health Care, Mijdrecht, NL).

Analysen im Rahmen der klinischen Studie BAY 57-9352: Imp. 100521 Open label, phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and biomarker status of BAY 57-9352 (KDR\VEGFR2-inhibitor) in a continuous dose schedule in subjects with advanced malignancies.

Ansprechpartner: Strecker R.
Tel: 0761-270-7412
Email: ralph.strecker@uniklinik-freiburg.de

Projektbeginn: 01.06.2005
Projektende: 31.05.2006

Hennig J.

Albert-Ludwigs-Universität Freiburg

• Bayer HealthCare AG, Firma

BAY57-100521